FIELD: medicine; biotechnology.
SUBSTANCE: present invention relates to biotechnology and medicine, in particular to a pharmaceutical composition that inhibits the CD95 signaling pathway, which has a pH in the range of 4 to 8, comprising said composition, 20 to 100 mM phosphate and 0.1 to 10 wt. % facilities, such as sorbitol, as well as a process for the preparation of said composition. Composition according to the invention comprises a mixture of isoforms of the APG101 fusion protein. These isoforms differ from the APG101 protein by length, namely, they can be truncated from the N-terminus to 16, 20 or 25 amino acids, have different lengths and may additionally contain amino acid substitutions and/or deletions and have at least 95 % identity with APG101 and are distributed within the pI-range of 4.0–8.5. Unmodified APG101 is present in said mixture in an amount not exceeding 1 mol. %.
EFFECT: present invention makes it possible to increase the efficacy of the agents for inhibiting the CD95 signaling pathway.
10 cl, 11 dwg, 1 ex, 4 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| SHORTENED CD95-Fc VARIANTS | 2013 |
|
RU2648146C2 |
| SINGLE-STRANDED CD40 RECEPTOR AGONIST PROTEINS | 2016 |
|
RU2745801C2 |
| PHARMACEUTICAL COMPOSITION OF THE FUSION PROTEIN OF THE TRANSFORMING GROWTH FACTOR BETA RECEPTOR AND ITS APPLICATION | 2019 |
|
RU2791683C2 |
| METHODS OF PURIFYING SINGLE-DOMAIN ANTIGEN-BINDING MOLECULES | 2009 |
|
RU2553214C2 |
| BIOLOGICALLY ACTIVATED DRUGS BASED ON CYTOKINES AND METHODS OF USING THEM | 2019 |
|
RU2819307C2 |
| QUANTITATIVE ESTIMATION OF MISFOLDED TNFR2:Fc | 2015 |
|
RU2698671C2 |
| HUMANISED ANTIBODY (H14,18) BASED ON MOUSE ANTIBODY 14,18, CONTACTING GD2, AND ITS FUSION WITH IL-2 | 2003 |
|
RU2366664C2 |
| MODIFIED INTERLEUKIN-7 PROTEIN AND METHODS FOR USE THEREOF | 2016 |
|
RU2708160C2 |
| FUSED PROTEINS IL-7 | 2004 |
|
RU2369616C2 |
| ACTIVIN-ActRIIa-Fc ANTAGONISTS AND USE THEREOF FOR TREATING OR PREVENTING BREAST CANCER | 2008 |
|
RU2473362C2 |
